Module

Current Assessment of Fibrosis

Source: Hepatitis Annual Update 2005

Current Assessment of Fibrosis


CME Program Director: Patrick J. Lynch, MD

Faculty:

  • Scott L. Friedman, MD

CME CREDIT INFORMATION

Release Date: 10/13/05

Expiration Date: 10/12/06


Physicians: maximum of 1 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Learning Objectives

Upon completion of this activity, participants should be able to:

  • Contrast the effectiveness of clinical algorithms compared to liver biopsy in assessing hepatic fibrosis

  • Describe the value of liver biopsy in assessing fibrosis

  • Understand the various commercial tests and those in development to measure hepatic fibrosis


Content includes:

  • Why Is Fibrosis Assessment So Important Now?
  • Types of Tests
  • Genomics
  • Microarray, Proteomics, and Glycomics
  • Novel Imaging Technologies
  • Serum Marker of Matrix Molecules or Modifying Enzymes
Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Northwestern University’s Feinberg School of Medicine and Clinical Care Options, LLC.

Educational grants provided by:

Educational grants support only the CME-certified components of this program.